SBIA | Recording Available for OTC Monograph Reform Webinar: OTC Sunscreen Drugs

Receive this email as a forward? Subscribe to CDER SBIA industry updates. FDA | CDER | Small Business and Industry Assistance WEBINARS OTC Monograph Reform: OTC Sunscreen Drugs Thank you for registering for this webinar. The recording is now available to view and/or share with colleagues. View Recording ABOUT THIS WEBINAR On September 24, 2021, FDA took steps aimed at improving the quality, safety, and efficacy of sunscreens as part of its implementation of new authorities for certain over-the-counter (OTC) drugs. FDA posted the deemed final order (DFO) for sunscreens which sets the current requirements for marketing OTC sunscreen products. FDA also posted the proposed order for sunscreens to amend and revise this deemed final order for OTC sunscreens products. This webinar will: Discuss the DFO for OTC sunscreen drugs and proposed order for OTC sunscreen drugs Compare and contrast the major provisions of the DFO for OTC sunscreen drugs and the proposed order for OTC sunscreen drug TOPICS Overview of OTC sunscreen drugs Relevant regulatory history for OTC sunscreen drugs Overview of OTC Monograph Reform DFO for OTC sunscreen drugs Proposed Order for OTC sunscreen drugs FDA SPEAKER Steven Adah, PhD. Associate Director of Monographs Office of Nonprescription Drugs (ONPD) | CDER | FDA   AUDIENCE General public with an interest in nonprescription (also known as over-the-counter or OTC) drugs Regulatory affairs professionals involved in the development or marketing of OTC drugs Foreign regulators following the development or marketing of OTC drugs Consultants focused on OTC drug development or marketing Clinical research coordinators Importers of OTC drugs CONTINUING EDUCATION Real-time attendance is required for the certificate of attendance which can be used in support of CEs for the following professional organizations.  Certificates are only available during the two weeks post-event. This course: has been pre-approved by RAPS as eligible for credits (appropriate to real-time attendance) towards a participant's RAC recertification upon full completion. has been pre-approved by SOCRA who accepts documentation of candidate participation in continuing education programs for re-certification if the program is applicable to clinical research regulations, operations or management, or to the candidate's clinical research therapeutic area. has been pre-approved by SQA as eligible for 1 non-GCP or non-GLP unit for every 1 hour of instructional time towards a participant's RQAP re-registration. has been approved by ACRP for continuing education in clinical research. ACRP will provide 1 ACRP contact hour for every 45-60 minutes of qualified material. The Small Business and Industry Assistance (SBIA) program in the Center for Drug Evaluation and Research provides guidance, education and updates for regulated industry. Register for Upcoming Training Watch Learning Library Recordings on YouTube Subscribe to CDER SBIA Email Updates Follow on LinkedIn Follow on Twitter

This is an automated message delivery system. Replying to this message will not reach the CDER SBIA staff. If you have comments or questions, contact us at CDERSBIA@fda.hhs.gov or 1-866-405-5367 or (301) 796-6707.   SUBSCRIBER SERVICES: Manage Subscriptions  |  Unsubscribe All  |  Help

This email was sent to ooseims.archieves@blogger.com using GovDelivery Communications Cloud on behalf of: U.S. Food and Drug Administration ·  10903 New Hampshire Ave · Silver Spring, MD ·  20993-0002 ·  1-888-INFO-FDA